Handbook for attention deficit hyperactivity disorder in adults

Handbook for Attention Deficit Hyperactivity Disorder in Adults

Volumn , Issue , 2013, Pages 1-216

  Asherson, Philip ^a,b   Young, Susan ^c,d   Adamou, Marios ^e   Bolea, Blanca ^f   Coghill, David ^g   Gudjonsson, Gisli ^c,d,h,i   Kustow, James ^j   Müller, Ulrich ^k,l,m,n,o,p   Pitts, Mark ^b   Thome, Johannes ^q  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BROADMOOR HOSPITAL   (United Kingdom)

^e SOUTH WEST YORKSHIRE PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^f Trincay Medical Services   (Cayman Islands)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h BRITISH PSYCHOLOGICAL SOCIETY   (United Kingdom)

ⁱ Health Professions Council (HPC)   (United Kingdom)

^j ADHD service   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^m Cambridgeshire and Peterborough Foundation NHS Trust   (United Kingdom)

ⁿ Rehabilitation and Recovery Team   (United Kingdom)

^o ADDENBROOKE S HOSPITAL   (United Kingdom)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^q UNIVERSITY OF ROSTOCK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019485189     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-908517-79-1     Document Type: Book

References (319)

1. Ford T, Goodman R, Meltzer H. The British child and adolescent mental health survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry. 2003;42:1203-1211.
2. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
3. Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204-211.
4. Faraone, SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165.
5. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: The NICE guideline on diagnosis and management of ADHD in children, young people, and adults. NICE website. 2008; www.nice.org.uk/CG072. Accessed April 13, 2012.
6. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21:1041.
7. Kooij SJJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association; 1994.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
10. World Health Organisation. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organisation; 2002. www.who.int/classifications/icd/en/GRNBOOK.pdf. Accessed August 25, 2012.
11. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People, and Adults. NICE website. www.nice.org.uk/CG072. Accessed August 25, 2012.
12. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161:1948-1956.
13. Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry. 1997;36:1211-1221.
14. Faraone S V, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163:1720-1729.
15. Barkley R, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; 2007.
16. Asherson, P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5:525-539.
17. American Psychiatric Association. DSM-5 development. A 06 Attention deficit disorder/ hyperactivity disorder. APA website. www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx?rid=383. Accessed August 25, 2012.
18. Brown TE. Executive functions and attention deficit hyperactivity disorder: implications of two conflicting views. Int J Disability, Development Education. 2006;53:35-46.
19. Kooij JJ, Buitelaar JK, van den Oord EJ, et al. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med. 2005;35:817-827.
20. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165.
21. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
22. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
23. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942-948.
24. Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry. 2003:42:1203-1211.
25. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
26. Kessler RC, Adler L, Berkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006:163:716-723.
27. Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204-211.
28. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165.
29. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194:273-277.
30. McArdle P, Prosser J, Kolvin I. Prevalence of psychiatric disorder: with and without psychosocial impairment. Eur Child Adolesc Psychiatry. 2004:13:347-353.
31. Faraone SV, Biederman J. What is the prevalence of adult ADHD ? Results of a population screen of 966 adults. J Atten Disord. 2005;9:384-391.
32. Kooij JJ, Buitelaar JK, van den Oord EJ, et al. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med. 2005;35:817-827.
33. Asherson P, Adamou M, Bolea B, et al. Is ADHD a valid diagnosis in adults? Yes. BMJ. 2010:340:c549.
34. Moncrieff J, Timimi S. Is ADHD a valid diagnosis in adults? No. BMJ. 2010;340:c547.
35. National Institute for Health and Clinical Excellent (NICE). Attention deficit hyperactivity disorder clinical guidelines 72: attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE website. www.nice.org.uk/CG72. Accessed August 25, 2012.
36. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
37. Todd RD, Rasmussen ER, Neuman RJ, et al. Familiality and heritability of subtypes of attention deficit hyperactivity disorder in a population sample of adolescent female twins. Am J Psychiatry. 2001;158:1891-1898.
38. Toplak ME, Pitch A, Flora DB, et al. The unity and diversity of inattention and hyperactivity/ impulsivity in ADHD: evidence for a general factor with separable dimensions. J Abnorm Child Psychol. 2009;37:1137-1150.
39. Toplak ME, Sorge GB, Flora DB, et al. The hierarchical factor model of ADHD: Invariant across age and national groupings? J Child Psychol Psychiatry. 2011;53:292-303.
40. Wood AC, Rijsdijk F, Asherson P, et al. Hyperactive-impulsive symptom scores and oppositional behaviors reflect alternate manifestations of a single liability. Behav Genet. 2009;39:447-460.
41. Taylor E, Chadwick O, Heptinstall E, et al. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry. 1996;35:1213-1226.
42. Thapar A, Harrington R, McGuffin P. Examining the comorbidity of ADHD-related behaviors and conduct problems using a twin study design. Br J Psychiatry. 2001;179:224-229.
43. Caspi A, Langley K, Milne B, et al. A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2008;65:203-210.
44. Langley K, Heron J, O'Donovan MC, et al. Genotype link with extreme antisocial behavior: the contribution of cognitive pathways. Arch Gen Psychiatry. 2010;67:1317-1323.
45. Asherson P, Gurling H. Quantitative and molecular genetics of ADHD. Curr Top Behav Neurosci. Curr Top Behav Neurosci. 2012;9:239-272.
46. Chen W, Zhou K, Sham P, et al. DSM-IV combined type ADHD shows familial association with sibling trait scores: a sampling strategy for QTL linkage. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1450-1460.
47. Barkley RA, Murphy KR, Dupaul GI, et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8:655-672.
48. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/ hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65:835-842.
49. Gau SS, Kessler RC, Tseng WL, et al. Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep. 2007;30:195-201.
50. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/ hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47:565-572.
51. Kooij JJS, Aeckerlin LP, Buitelaar JK. Functioning, comorbidity and treatment of 141 adults with attention deficit hyperactivity disorder (ADHD) at a Psychiatric Outpatients' Department. [Dutch]. Ned Tijdschr Geneeskd. 2001;145:1498-1501.
52. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. 2007;96:1269-1274.
53. Castellanos FX, Tannock, R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002;3:617-628.
54. Cubillo A, Halari R, Smith A, et al. A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex. 2011;48:194-215.
55. Cubillo A, Rubia K. Structural and functional brain imaging in adult attention-deficit/ hyperactivity disorder. Expert Rev Neurother. 2010;10:603-620.
56. Tye C, McLoughlin G, Kuntsi J, et al. Electrophysiological markers of genetic risk for attention deficit hyperactivity disorder. Expert Rev Mol Med. 2011;13:e9.
57. Thapar A, Rice F, Hay D, et al. Prenatal smoking might not cause attention-deficit/hyperactivity disorder: evidence from a novel design. Biol Psychiatry. 2009;66:722-727.
58. Coghill D, Nigg J, Rothenberger A, et al. Whither causal models in the neuroscience of ADHD? Dev Sci. 2005:8:105-114.
59. Johnson KA, Wiersema JR, Kuntsi J. What would Karl Popper say? Are current psychological theories of ADHD falsifiable? Behav Brain Funct. 2009;5:15.
60. Stevens SE, Sonuga-Barke EJ, Kreppner JM, et al. Inattention/overactivity following early severe institutional deprivation: presentation and associations in early adolescence. J Abnorm Child Psychol. 2008;36:385-398.
61. Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol. 2000;18:1-16.
62. Burt SA. Rethinking environmental contributions to child and adolescent psychopathology: a meta-analysis of shared environmental influences. Psychol Bull. 2009;135:608-637.
63. Boomsma DI, Saviouk V, Hottenga JJ, et al. Genetic epidemiology of attention deficit hyperactivity disorder (ADHD index) in adults. PLoS One. 2010;5:e10621.
64. Freitag CM, Rohde LA, Lempp T, Romanos M. Phenotypic and measurement influences on heritability estimates in childhood ADHD. Eur Child Adolesc Psychiatry. 2010;19:311-323.
65. Li D, Sham PC, Owen MJ, et al. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet. 2006;15:2276-2284.
66. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126:51-90.
67. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet. 2009;126:13-50.
68. Elmans G, Pauls DL, Buitelaar JK, et al. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry. 2011;168:365-377.
69. Williams NM, Franke B, Mick E, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry. 2011;169:195-204.
70. Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet. 2010;376:1401-1408.
71. Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behavior of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377:494-503.
72. Stevenson J, Sonuga-Barke E, McCann D, et al The role of histamine degradation gene polymorphisms in moderating the effects of food additives on children's ADHD symptoms. Am J Psychiatry. 2010;167:1108-1111.
73. Nigg JT, Nikolas M, Mark Knottnerus G., et al. Confirmation and extension of association of blood lead with attention-deficit/hyperactivity disorder (ADHD) and ADHD symptom domains at population-typical exposure levels. J Child Psychol Psychiatry. 2010;51:58-65.
74. Aylward GP. Neurodevelopmental outcomes of infants born prematurely. J Dev Behav Pediatr. 2005;26:427-440.
75. Oesterheld JR, Wilson A. ADHD and FAS (Letter to the editor). J Am Acad Child Adolesc Psychiatry. 1997;36:1163.
76. Steinhausen HC, Willms J, Spohr HL. Long-term psychopathological and cognitive outcome of children with fetal alcohol syndrome. J Am Acad Child Adolesc Psychiatry. 1993;32:990-994.
77. Streissguth AP, Bookstein FL, Sampson PD, Barr HM. Attention: Prenatal alcohol and continuities of vigilance and attentional problems from 4 through 14 years. Dev Psychopathol. 1995;7:419-446.
78. Rutter M, Colvert E, Kreppner J, et al. Early adolescent outcomes for institutionally-deprived and non-deprived adoptees. I: disinhibited attachment. J Child Psychol Psychiatry. 2007;48:17-30.
79. Biederman J, Petty CR, Clarke A, et al. Predictors of persistent ADHD: An 11-year follow-up study. J Psychiatr Res. 2010;45:150-155.
80. Boonstra AM, Oosterlaan J, Sergeant JA, et al. Executive functioning in adult ADHD: a meta-analytic review. Psychol Med. 2005;35:1097-1108.
81. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/ hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004;18:485-503.
82. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121:65-94.
83. Sergeant JA. Modeling attention-deficit/hyperactivity disorder: a critical appraisal of the cognitive-energetic model. Biol Psychiatry. 2005;57:1248-1255.
84. Marco R, Miranda A, Schlotz W, et al. Delay and reward choice in ADHD: an experimental test of the role of delay aversion. Neuropsychology. 2009:23:367-380.
85. Sonuga-Barke EJ. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev. 2003;27:593-604.
86. Kuntsi J, Wood AC, Rijsdijk F, et al. Separation of cognitive impairments in attention-deficit/ hyperactivity disorder into 2 familial factors. Arch Gen Psychiatry. 2010:67:1159-1167.
87. Halperin JM, Trampush JW, Miller CJ, et al. Neuropsychological outcome in adolescents/young adults with childhood ADHD: profiles of persisters, remitters and controls. J Child Psychol Psychiatry. 2008;49:958-966.
88. Sagvolden T, Johansen EB, Aase H, et al. A dynamic developmental theory of attention-deficit/ hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci. 2005;28:397-419.
89. Broyd SJ, Demanuele C, Debener S, et al. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev. 2009;33:279-296.
90. Kendler KS, Neale MC. Endophenotype: a conceptual analysis. Mol Psychiatry. 2010;15:789-797.
91. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA. 2007;104:19649-19654.
92. Paloyelis Y, Mehta MA, Kuntsi J, et al. Functional MRI in ADHD: a systematic literature review. Expert Rev Neurother. 2007;7:1337-1356.
93. Castellanos FX, Margulies DS, Kelly C, et al. Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63:332-337.
94. Liston C, Malter Cohen M, Teslovich T, et al. Atypical prefrontal connectivity in attention-deficit/ hyperactivity disorder: pathway to disease or pathological end point? Biol Psychiatry. 2011;69:1168-1177.
95. Banaschewski T, Brandeis D, Heinrich H, et al. Questioning inhibitory control as the specific deficit of ADHD-evidence from brain electrical activity. J Neural Transm. 2004;111:841-864.
96. McLoughlin G, Albrecht B, Banaschewski T, et al. Electrophysiological evidence for abnormal preparatory states and inhibitory processing in adult ADHD. Behav Brain Funct. 2010;6:66.
97. Del Campo N, Muller U, Sahakian B. Neural and behavioral endophenotypes in ADHD. In, JW Dalley, CS Carter (eds), Brain Imaging in Behavioral Neuroscience (Current Topics in Behavioral Neurosciences, CTBN Series) New York, NY: Springer; 2012.
98. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302:1084-1091.
99. Volkow ND, Wang GJ, Newcorn JH, et al. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. Mol Psychiatry. 2011;16:1147-1154.
100. Fusar-Poli P, Rubia K, Rossi G, et al. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012;169:264-272.
101. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5:525-539.
102. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization;2002. Accessed August 25, 2012.
103. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS). Psychol Med. 2005;35:245-256.
104. Barkley MA, Murphy RA. Attention-Deficit Hyperactivity Disorder: a Clinical Workbook. Third ed. New York: Guildford Press; 2006.
105. Kooij JJS, Francken MH. Diagnostic Interview for ADHD Adults (DIVA scale). DIVA Foundation website. www.ukaan.org/clinicians_resource.htm. Accessed August 25, 2012.
106. Epstein JN, Kollins SH. Psychometric properties of an adult ADHD diagnostic interview. J Atten Disord. 2006;9:504-514.
107. Weiss Scale. www.caddra.ca/cms4/pdfs/caddraGuidelines2011WFIRS _S.pdf. Accessed August 25, 2012.
108. Bálint S, Czobor P, Komlósi S, Mészáros á, Simon S, Bitter I. Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychol Med. 2009;39:1337-1345.
109. Young S. Attention Deficit Hyperactivity Disorder. In: Young S, Kopelman M, Gudjonsson G, eds, Forensic Neuropsychology In Practice: A Guide to Assessment and Legal Processes. New York, NY: Oxford University Press; 2009:81-107.
110. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/ hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004, 18:485-503.
111. Quinlan DM. Assesment of attention deficit/hyperactivity disorder and comorbities. In: TE Brown, ed, Attention-Deficit Disorders and Comorbidity in Children, Adolescents, and Adults. Washington DC: American Psychiatric Press; 2001.
112. Gudjonsson G, Young S. An overlooked vulnerability in a defendant: attention deficit hyperactivity disorder (ADHD) and a miscarriage of justice. Legal and Criminological Psychology. 2006;11:211-218.
113. Young S, Morris RG, Toone BK, Tyson C. Spatial working memory and strategy formation in adults diagnosed with attention deficit hyperactivity disorder. Pers Individ Dif. 2006;41:653-661.
114. Roberston IH, Ward T, Ridgeway V, Nimmo-Smith I. The Test of Everyday Attention. Bury St Edmunds: Thames Valley Test; 1994.
115. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. Oxford: O xford University Press; 2004.
116. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.
117. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York, NY: Oxford University Press; 1998.
118. Cairnes E, Cammock T. Development of a more reliable version of the Matching Familiar Figures Test. Dev Psychol. 1978:14:555-556.
119. Young S, Channon S, Toone BK. Neuropsychological assessment of attention deficit hyperactivity disorder in adulthood. Clin Neuropsychol Assess. 2000;1:283-294.
120. Young S, Gudjonsson G. Neurospychological correlates of the YAQ-S self-reported ADHD symptomatology, emotional and social problems, and delinquent behaviours. Br J Psychiatry. 2005;44:47-57.
121. Trenerry MR, Crosson B, DeBoe J, Leber WR. Stroop Neuropsychological Screening Test Manual. Odessa, FL: Psychological Assessment Resources; 1989.
122. Young S, Morris RG, Bramham J, Tyson C. Inhibitory dysfunction on the Stroop in adults diagnosed with attention deficit hyperactivity disorder. Pers Individ Dif. 2006;41:1377-1384.
123. Young S, Morris RG, Toone BK, Tyson, C. Planning ability in adults diagnosed with attention-deficit/hyperactivity disorder: A deficit in planning ability. Neuropsychology. 2007;21: 581-589.
124. Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/ hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD clinical diagnostic scale. Arch General Psych. 2010;67:1168-1178.
125. Barkley R, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York: Guilford Press; 2007.
126. Brown TE. Executive functions and attention deficit hyperactivity disorder: Implications of two conflicting views. Int J Disabil Dev Edu. 2006;53:35-46.
127. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5:525-539.
128. Barkley RA, Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry. 2010;49:503-513.
129. Skirrow C, McLoughlin G, Kuntsi J, Asherson P. Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurother. 2009;9:489-503.
130. Skirrow C, Hosang GM, Farmer AE, Asherson P. An update on the debated association between ADHD and bipolar disorder across the lifespan. J Affect Disord. 2012.
131. Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psych. 2005;58:125-131.
132. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68:93-101.
133. Rosler M, Retz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psych. 2010;11:709-718.
134. Kuntsi J, Eley TC, Taylor A, et al. Co-occurrence of ADHD and low IQ has genetic origins. Am J Med Genet B Neuropsychiatr Genet. 2004;124B:41-47.
135. National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder: the NICE Guideline on Diagnosis and Managment of ADHD in Children, Young People and Adults. Clinical Guidelines, CG72. NICE website. www.nice.org.uk/CG72. Accessed August 25, 2012.
136. American Psychiatry Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revision. Washington DC: American Psychiatric Association; 2000.
137. Willcutt EG, Pennington BF, Olson RK, DeFries JC. Understanding comorbidity: a twin study of reading disability and attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:709-714.
138. Ronald A, Simonoff E, Kuntsi J, Asherson P, Plomin R. Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry. 2008;49:535-542.
139. Caspi A, Langley K, Milne B, et al. A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2008;65:203-210.
140. Scheres A, Milham MP, Knutson B, Castellanos FX. Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder. Biol Psych. 2007;61:720-724.
141. Paloyelis Y, Asherson P, Mehta MA, Faraone SV, Kuntsi J. DAT 1 and CO MT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls. Neuropsychopharmacology. 2010;35:2414-2426.
142. Andreou P, Neale BM, Chen W, et al. Reaction time performance in ADHD: improvement under fast-incentive condition and familial effects. Psychol Med. 2007;37:1703-1715.
143. Wilson JJ, Levin FR. Attention deficit hyperactivity disorder (ADHD) and substance use disorders. Curr Psychiatry Rep. 2001;3:497-506.
144. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995; 152: 1652-1658.
145. Ohlmeier MD, Peters K, Te Wildt BT, Zedler M, Ziegenbein M, Wiese B, et al. Comorbidity of alcohol and substance dependence with attention-deficit/hyperactivity disorder (ADHD). Alcohol Alcohol. 2008; 43: 300-304.
146. Lambert N. The contribution of childhood ADHD, conduct problems, and stimulant treatment to adolescent and adult tobacco and psychoactive substance abuse. Ethical Hum Psychol Psychiatry. 2005;7:197-221.
147. Wilens TE, Kwon A, Tanguay S, et al. Characteristics of adults with attention deficit hyperactivity disorder plus substance use disorder: the role of psychiatric comorbidity. Am J Addict. 2005;14:319-327.
148. Nelson A, Galon P. Exploring the relationship among ADHD, stimulants, and substance abuse. J Child Adolesc Psychiatr Nurs. 2012;25:113-118.
149. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185.
150. Meinzer MC, Pettit JW, Leventhal AM, Hill RM. Explaining the covariance between attentiondeficit hyperactivity disorder symptoms and depressive symptoms: the role of hedonic responsivity. J Clin Psychol. 2012;[Epub ahead of print].
151. Edbom T, Lichtenstein P, Granlund M, Larsson JO. Long-term relationships between symptoms of attention deficit hyperactivity disorder and self-esteem in a prospective longitudinal study of twins. Acta Paediatr. 2006;95:650-657.
152. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31:416-425.
153. Doyle BD. Understanding and Treating Adults with Attention Deficit Hyperactivity Disorder. Washington DC, American Psychiatric Publishing; 2006.
154. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
155. Magon R, Müller U. ADHD with comorbid substance use disorder: review of treatment. Adv Psychiatr. 2012;18:436-446.
156. Yen JY, Yen CF, Chen CS, Tang TC, Ko CH. The association between adult ADHD symptoms and internet addiction among college students: the gender difference. Cyberpsychol Behav. 2009;12:187-191.
157. Breyer JL, Botzet AM, Winters KC, Stinchfield RD, August G, Realmuto G. Young adult gambling behaviors and their relationship with the persistence of ADHD. J Gambl Stud. 2009;25:227-238.
158. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21-31.
159. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160:1909-1918.
160. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev. 2003;27:615-621.
161. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry. 2003;64(suppl 11):9-13.
162. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2006;256(suppl 1):i26-i31.
163. Fones CS, Pollack MH, Susswein L, Otto M. History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder. J Affect Disord. 2000;58:99-106.
164. Dodson WW. Pharmacotherapy of adult ADHD. J Clin Psychol. 2005;61:589-606.
165. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurotherapeutics. 2005;5:525-539.
166. Gurkan K, Bilgic A, Turkoglu S, Kilic BG, Aysev A, Uslu R. Depression, anxiety and obsessivecompulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol. 2010;24:1810-1818.
167. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26:212-221.
168. Scott NG, Ripperger-Suhler J, Rajab MH, Kjar D. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2010;20:197-203.
169. Babcock T, Ornstein CS. Comorbidity and its impact in adult patients with attention-deficit/ hyperactivity disorder: a primary care perspective. Postgrad Med. 2009;121:73-82.
170. Geller DA, Biederman J, Faraone SV, et al. Attention-deficit/hyperactivity disorder in children and adolescents with obsessive-compulsive disorder: fact or artifact? J Am Acad Child Adolesc Psychiatry. 2002;41:52-58.
171. Fogel J. An epidemiological perspective of obsessive-compulsive disorder in children and adolescents. Can Child Adolesc Psychiatr Rev. 2003;12:33-36.
172. Geller D, Petty C, Vivas F, Johnson J, Pauls D, Biederman J. Further evidence for co-segregation between pediatric obsessive compulsive disorder and attention deficit hyperactivity disorder: a familial risk analysis. Biol Psych. 2007;61:1388-1394.
173. Bandelow B. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr. 2008;13(9 suppl 14):37-46.
174. National Institute for Health and Clinical Excellence (NICE). Attention Deficit Hyperactivity Disorder: NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults. NICE website. www.nice.org.uk/nicemedia/pdf/CG72NiceGuidelinev3.pdf. Accessed August 25, 2012.
175. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21:10-41.
176. Kooij S. Adult ADHD Diagnostic Assessment and Treatment. Amsterdam: Pearson; 2010.
177. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
178. Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009;12:1137-1147.
179. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96:145-154.
180. Koesters M, Becker T, Kilian R, Fergert JM, Weinmann S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol. 2009;23:733-744.
181. Farone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24:24-29.
182. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
183. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25:157-169.
184. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/ hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754-763.
185. British National Formulary (BNF). Methylphenidate hydrochloride. BNF website. www.bnf.org/bnf/bnf/current/86032.htm?q=methylphenidate&t=search&ss=tex t&p=3#_86032. Accessed August 25, 2012.
186. Food and Drug Administration (FDA). FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. FDA website. www.fda.gov/Drugs/DrugSafety/ucm279858.htm. Accessed August 25, 2012.
187. Poncin Y, Sukhodolsky DG, McGuire J, Scahill L. Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry. 2007;16(suppl 1):78-88.
188. Concerta Extended Release Prescribing Information. Titusville, NJ: McNeil Pediatrics. www.concerta.net/sites/default/files/pdf/Prescribing_Info-short.pdf#zoom=56. Accessed August 25, 2012.
189. Stifel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33:821-842.
190. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196-204.
191. Bazire S. Psychotropic Drug Directory 2010: the Professionals' Pocket Handbook and Aide Memoire. Aberdeen: HealthComm UK; 2011.
192. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96-106.
193. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456-463.
194. Weikop P, Egestad B, Kehr J. Application of triple-probe microdialysis for fast pharmacokinetic/ pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. J Neurosci Methods. 2004;140:59-65.
195. Banaschewski T, Coghill D, Santosh P, et al. Long acting medications for the hyperkinetic disorders: a systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry. 2006;15:476-495.
196. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced ER amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69:1437-1448.
197. Stahl SM, Mignon L. Stahl's Illustrated Attention Deficit Hyperactivity Disorder. New York: Cambridge University Press; 2009.
198. Pennick M. Absorption of lisdexamphetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327.
199. Silva RR, Skimming JW, Muniz R. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. Clin Pediatr (Phila). 2010;49:840-851.
200. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-1904.
201. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673-2683.
202. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry. 2003;53:112-120.
203. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18:107-113.
204. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/ hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29:44-50.
205. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22:498-512.
206. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222-230.
207. Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, van Wyk GW. Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis. J Atten Disord. 2010;41:335-231.
208. Summary of product characteristics: Strattera 10mg, 18mg, 25mg, 40mg, 60mg or 80mg hard capsules. www.medicines.org.uk/emc/medicine/14482/SPC/Strattera++10mg,+18mg,+25mg, +40mg,+60mg+or+80mg+hard+capsules/. Accessed August 25, 2012.
209. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescent with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13:53-63.
210. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011;65:611-617.
211. Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM. 2010;12:158-161.
212. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57:608-618.
213. Wuo-Silva R, Fukushiro DF, Borçoi AR, et al. Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol. 2011;16:565-579.
214. Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/ hyperactivitydisorder. Ann Clin Psychiatry. 2012;24:23-37.
215. Findling RL, Greenhill LL, McNamara NK, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivitydisorder. J Child Adolesc Psychopharmacol. 2007;17:433-445.
216. Zarinara AR, Mohammadi MR, Hazrati N, et al. Venlafaxine versus methylphenidate in pediatric outpatients with attentiondeficithyperactivitydisorder: a randomized, double-blind comparison trial. Hum Psychopharmacol. 2010;25:530-535.
217. Agarwal V, Sitholey P. Combination of atomoxetine and methylphenidate in attention deficit/ hyperactivity disorder: a case report. J Can Acad Child Adolesc Psychiatry. 2008;17:160.
218. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194:273-277.
219. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165.
220. Young S, Gudjonsson G. Growing out of attention-deficit/hyperactivity disorder: the relationship between functioning and symptoms. J Atten Disord. 2008;12:162-169.
221. Young S, Murphy CM, Coghill D. Avoiding the 'twilight zone': Guidance and recommendations on ADHD and the transition between child and adult services. BMC Psychiatry. 2011;11:174.
222. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816-818.
223. Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Dev Disabil Res Rev. 1999;5:243-250.
224. Young S, Amarasinghe JA. Practitioner Review: non-pharmacological treatments for ADHD: A lifespan approach. J Child Psychol Psychiatry. 2010;51:116-133.
225. Young S. Coping strategies used by ADHD adults. Pers Individ Dif. 2005;38:809-816.
226. Wender P. Attention Deficit Hyperactivity Disorder in Children and Adults. New York: Oxford University Press; 2000.
227. Dalsgaard S, Mortensen PB, Frydenberg M, et al. Conduct problems, gender and the adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry. 2002;181:416-421.
228. Young S, Toone B, Tyson C. Comorbidity and psychosocial profile of adults with attention deficit hyperactivity disorder. Pers Individ Dif. 2003;35:743-755.
229. Young S, Bramham J, Gray K, Rose E. The experience of receiving a diagnosis and treatment of ADHD in adulthood: a qualitative study of clinically referred patients using Interpretative Phenomenological Analysis. J Atten Disord. 2008;11:493-503.
230. Young S, Gray K, Bramham J. A phenomenological analysis of the experience of receiving a diagnosis and treatment of ADHD in adulthood: a partner's perspective. J Atten Disord. 2009;12:299-307.
231. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD-results of an open study of 43 patients. J Atten Disord. 2006;10:150-159.
232. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43:831-842.
233. Emilsson B, Gudjonsson G, Sigurdsson JF, et al. Cognitive behavior therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC Psychiatry. 2011;11:116-125.
234. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA. 2010;304:875-880.
235. Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry. 2010;167:958-968.
236. Virta M, Salakari A, Antila M,et al. Short cognitive behavioral therapy and cognitive training for adults with ADHD-a randomized controlled pilot study. Neuropsychiatr Dis Treat. 2010;10:443-453.
237. Hirvikoski T, Waaler E, Alfredsson J, et al. Reduced ADHD symptoms in adults with ADHD after structured skills training group: Results from a randomized controlled trial. Behav Res Ther. 2011;49:175-185.
238. Bramham J, Young S, Bickerdike A, et al. Evaluation of group cognitive behavioral therapy for adults with ADHD. J Atten Disord. 2009;12:434-441.
239. National Institute for Health and Clinical Excellence (NICE). Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guideline 72.; NICE website. 2009. www.nice.org.uk/CG72. Accessed August 25, 2012.
240. Stevenson CS, Whitmont S, Bornholt L, et al. A cognitive remediation program for adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 2002;36:610-616.
241. Young S, Bramham J. Cognitive Behavoiural Therapy for ADHD in Adolescents and Adults: A Psychological Guide to Practice. Chichester: John Wiley and Sons Ltd; 2012.
242. Hull CL. Principles of Behavior. New York: Appleton-Century-Crofts; 1943.
243. Linehan MM. Dialectical behavior therapy for treatment of borderline personality disorder: implications for the treatment of substance abuse. NIDA Research Monographs. 1993;137:201-215.
244. Hollin CR, Palmer EJ. Offending behavior programmes: controversies and resolutions. In: Holin CJ, Palmer EJ, eds. Offending Behavior Programmes: Development, Application and Controversies. Chichester: John Wiley and Sons; 2006.
245. Young SJ, Ross RR. R&R2 for ADHD youths and adults. A Prosocial Competence Training Program. Ottawa: Cognitive Centre of Canada; 2007.
246. Chen W, Zhou K, Sham P, et al. DSM-IV combined type ADHD shows familial association with sibling trait scores: a sampling strategy for QTL linkage. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1450-1460.
247. Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol. 2000;18:1-16.
248. Humphreys C, Garcia-Bournissen F, Ito S, et al. Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Phys. 2007;53:1153-1155.
249. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:474-484.
250. Linnet KM, Dalsgaard S, Obel C, et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry. 2003;160:1028-1040.
251. Rodriguez A, Bohlin G. Are maternal smoking and stress during pregnancy related to ADHD symptoms in children? J Child Psychol Psychiatry. 2005;46:246-254.
252. de Zeeuw P, Zwart F, Schrama R, van Engeland H, Durston S. Prenatal exposure to cigarette smoke or alcohol and cerebellum volume in attention-deficit/hyperactivity disorder and typical development. Transl Psychiatry. 2012;2:e84.
253. Grizenko N, Shayan YR, Polotskaia A, et al. Relation of maternal stress during pregnancy to symptom severity and response to treatment in children with ADHD. J Psychiatr Neurosci. 2008; 33:10-16.
254. Thapar A, Rice F, Hay D, et al. Prenatal smoking might not cause attention-deficit/hyperactivity disorder: evidence from a novel design. Biol Psychiatry. 2009;66:722-727.
255. Aarnoudse-Moens CS, Weisglas-Kuperus N, van Goudoever JB, et al. Meta-analysis of neurobehavioral outcomes in very preterm and/or very low birth weight children. Pediatrics. 2009;124:717-728.
256. Dahl LB, Kaaresen P, Tunby J, et al. Emotional, behavioral, social, and academic outcomes in adolescents born with very low birth weight. Pediatrics. 2006;118:e449-e459.
257. Shum D, Neulinger K, O'Callaghan M, et al. Attentional problems in children born very preterm or with extremely low birth weight at 7-9 years. Arch Clin Neuropsychol. 2008;23:103-112.
258. Milberger S, Biederman J, Faraone SV, et al. Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: issues of gene-environment interaction. Biol Psychiatry. 1997; 41:65-75.
259. Hackett P, Kristensen JH, Hale TW, Paterson R, Ilett KF. Methylphenidate and breast-feeding. Pharmacother. 2006;40:1890-1891.
260. European Medicines Agency (EMA). Modafinil summary of product characteristics. EMA website. www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/ Modafinil_31/WC500099178.pdf. Accessed August 24, 2012.
261. Taddio A, Ito S. Drugs and breastfeeding. In: Koren G, ed. Maternal-Fetal Toxicology, A Clinician's Guide. 3rd edition. New York, US: Dekker M, Inc; 2001: 177-233.
262. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psych Med. 2006;36:159-165.
263. Young S, Adamou M, Bolea B, Gudjonsson G, Müller U, Pitts M, Thome J, Asherson P. The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry. 2011;11:116.
264. Young S, Gudjonsson G, Ball S, Lam J. Attention deficit hyperactivity disorder in personality disordered offenders and the association with disruptive behavioral problems. J Forens Psychiatry Psychol. 2003;14:491-505.
265. Young S, Gudjonsson GH, Misch P, et al. Prevalence of ADHD symptoms among youth in a secure facility: The consistency and accuracy of self- and informant-report ratings. J Forens Psychiatry Psychol. 2010;21:238-246.
266. Young S, Gudjonsson GH, Wells J, et al. Attention Deficit Hyperactivity Disorder and critical incidents in a Scottish prison population. Pers Individ Dif. 2009;46:265-269.
267. Young S, Wells J, Gudjonsson GH. Predictors of offending among prisoners: the role of attention deficit hyperactivity disorder (ADHD) and substance use. J Psychopharmacol. 2011;25:1524-1532.
268. Gudjonsson GH, Wells J, Young S. Motivation for offending among prisoners and the relationship with Axis I and Axis II disorders and ADHD symptoms. Per Individ Dif. 2011;50:64-68.
269. Young S. Attention Deficit Hyperactivity Disorder. In, Young S, Kopelman M, Gudjonsson G. (eds), Forensic Neuropsychology In Practice: A Guide to Assessment and Legal Processes. New York: Oxford University Press; 2009: 81-107.
270. Gudjonsson GH, Young S, Bramham J. Interrogative suggestibility in adults diagnosed with attention-deficit hyperactivity disorder (ADHD). A potential vulnerability during police questioning. Pers Individ Dif. 2007;43:737-745.
271. Gudjonsson GH, Sigurdsson JF, Einarsson E, Bragason OO, Newton AK. Interrogative suggestibility, compliance and false confessions among prison inmates and their relationship with attention deficit hyperactivity disorder. Psychol Med. 2008;38:1037-1044.
272. Gudjonsson GH, Sigurdsson JF, Sigfusdottir ID, Young S. False confessions to police and their relationship with conduct disorder, ADHD, and life adversity Pers Individ Dif. 2012;52:696-701.
273. Medford S, Gudjonsson GH, Pearse J. The efficacy of the appropriate adult safeguard during police interviewing. Leg Criminol Psychol. 2003;8:253-266.
274. Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet. 376:1401-1408.
275. Gudjonsson G, Young, S. An overlooked vulnerability in a defendant: attention deficit hyperactivity disorder (ADHD) and a miscarriage of justice. Leg Criminol Psychol. 2006;11:211-218.
276. Gudjonsson GH, Sigurdsson JF, Sigfusdottir ID, Young S. A national epidemiological study of offending and its relationship with ADHD symptoms and associated risk factors. J Atten Disord. In press.
277. Young S, Misch P, Collins P, Gudjonsson GH. Predictors of institutional behavioural disturbance and offending in the community among young offenders. J Forens Psychiatry Psychol. 2011;22:72-86.
278. Gudjonsson GH, Sigurdsson JF, Adalssteinsson T, Young S. The relationship between ADHD symptoms, mood instability, and self-reported offending. J Atten Disord. In press.
279. Young SJ, Ross RR. R&R2 for Youths and Adults with Mental Health Problems: A Prosocial Competence Training Program. Ottawa: Cognitive Centre of Canada; 2007.
280. Emilsson B, Gudjonsson G, Sigurdsson JF, et al. Cognitive behavior therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC Psychiatry. 2011;11:116-125.
281. Young S, Hopkin G, Perkins D, Farr C, Doidge A, Gudjonsson GH. A controlled trial of a cognitive skills program for personality disordered offenders. J Atten Disord. In press.
282. Goldberg D, Huxley P. Mental Illness in the Community: The Pathway to Psychiatric Care. London: Tavistock; 1980.
283. Sayal K, Taylor E, Beecham J, Byrne P. Pathways to care in children at risk of attention-deficit hyperactivity disorder. Br J of Psychiatry. 2002;181:43-48.
284. Tettenborn M, Prasad S, Poole L, et al. The provision and nature of ADHD services for children/ adolescents in the UK: results from a nationwide survey. Clin Child Psychol Psychiatry. 2008;13:287-304.
285. Verity R, Coates J. Service innovation: transitional attention-deficit hyperactivity disorder clinic. Psychiatr Bull. 2007;31:99-100.
286. Singh SP. Transition of care from child to adult mental health services: the great divide. Curr Opin Psychiatry. 2009;22:386-390.
287. Singh SP, Paul M, Ford T, Kramer T, Weaver T. Transitions of care from Child and Adolescent Mental Health Services to Adult Mental Health Services (TRACK Study): a study of protocols in Greater London. BMC Health Serv Res. 2008;8:135.
288. Sayal K, Ford T, Goodman R. Trends in recognition of and service use for attention-deficit hyperactivity disorder in britain, 1999-2004. Psychiatr Serv. 2010;61:803-810.
289. Hoagwood K, Kelleher KJ, Feil M, Comer DM. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:198-206.
290. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:975-894.
291. Wasserman RC, Kelleher KJ, Bocian A. Identification of attentional and hyperactivity problems in primary care: a report from pediatric research in office settings and the ambulatory sentinel practice network. Pediatrics. 1999;103:E38.
292. Zito JM, Safer DJ, dosReis S, Magder LS, Riddle MA. Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull. 1997;33:143-147.
293. Gardner W, Kelleher KJ, Wasserman R, et al. Primary care treatment of pediatric psychosocial problems: A study from pediatric research in office settings and ambulatory sentinel practice network. Pediatrics. 2000;106:E44.
294. Nøvik TS, Hervas A, Ralston SJ, et al; for the ADORE Study Group. Influence of gender on attention-deficit/hyperactivity disorder in Europe-ADORE. Eur Child Adolesc Psychiatry. 2006;15:115-124.
295. Bussing R, Zima BT, Belin TR. Differential access to care for children with ADHD in special education programs. Psychiatr Serv. 1998;49:1226-1229.
296. Zito JM, Safer DJ, dosReis S, Riddle MA. Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland. J Am Acad Child Adolesc Psychiatry. 1998;37:179-184.
297. Bussing R, Zima BT, Gary FA, et al. Social networks, caregiver strain, and utilization of mental health services among elementary school students at high risk for ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:842-850.
298. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry. 2004;13:17-30.
299. Taylor E, Sergeant J, Döpfner M, et al. Clinical guidelines for hyperkinetic disorder. European Society for Child and Adolescent Psychiatry. Eur Child Adolesc Psychiatry. 1998;7:184-200.
300. National Institute for Health and Clinical Excellence (NICE). NICE Guideline CG72: Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Website. www.nice.org.uk/CG72. Accessed August 24, 2012.
301. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21:195-206.
302. Hinnenthal JA, Perwien AR, Sterling KL. A comparison of service use and costs among adults with ADHD and adults with other chronic diseases. Psychiatr Serv. 2005;56:1593-1599.
303. Hakkaart-van Roijen L, Zwirs BW, Bouwmans C, et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2007;16:316-326.
304. De Ridder A, De Graeve D. Healthcare use, social burden, and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Investig. 2006;26:75-90.
305. Griffin SC, Weatherly HL, Richardson GA, Drummond MF. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD. Eur J Health Econ. 2008;9:137-145.
306. Kleinman NL, Durkin M, Melkonian A, Markosyan K. Incremental employee health benefit costs, absence days, and turnover among employees with ADHD and among employees with children with ADHD. J Occup Environ Med. 2009;51:1247-1255.
307. Kessler RC, Lane M, Stang PE, Van Brunt DL. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med. 2009;39:137-147.
308. Halmoy A, Fasmer OB, Gillberg C, Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord. 2009;13:175-187.
309. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/ hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65:835-842.
310. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/ hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47:565-572.
311. Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol. 2010;25:157-173.
312. Kewley GD, Orford E. Attention deficit hyperactivity disorder is underdiagnosed and undertreated in Britain: Diagnosis needs tightening. BMJ. 1998;316:1594-1596.
313. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194:273-277.
314. Wong IC, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)-a pharmacoepidemiological and qualitative study. Health Technol Assess. 2009;13:1-120.
315. Matheson L, Asherson P, Wong I, et al. P-876-Adult ADHD patients' experiences of impairment, accessing services and treatment management-a qualitative study in England. Eur Psychiatry. 2012;27:1.
316. Adamou M. Effects and Determinants of Service Provision for Adults with ADHD. PhD Thesis. University of Kent; 2011.
317. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
318. Marcer H, Finlay F, Baverstock A. ADHD and transition to adult services-the experience of community paediatricians. Child Care Health Dev. 2008;34:564-566.
319. Report of the conference on the use of stimulant drugs in the treatment of behaviorally disturbed young school children. Psychopharmacol Bull. 1971;7:23-29.